- Home
- SHPH vs OIOWW Comparison
SHPH vs OIOWW Comparison
Compare SHPH & OIOWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHPH | OIOWW |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | SHPH | OIOWW |
|---|---|---|
| Price | $0.88 | N/A |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 64.0K | N/A |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | N/A |
| 52 Week High | $5.59 | N/A |
Technical Indicators
Market Signals| Indicator | SHPH | OIOWW |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | N/A |
| Support Level | $0.80 | N/A |
| Resistance Level | $2.00 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 26.92 | 0.00 |
Price Performance
Historical ComparisonAbout SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.